The current NeuroDelta Ltd company was established in 2007 to hold intellectual property, including the UK registered NeuroDelta trademark developed by Nat Milton during his commercial work. For commercial use of this intellectual property please email NeuroDelta Ltd directly.
Details of Nat Milton's published academic research is available on the Research page. This site also contains a Bioinformatics Protocol page detailing methods for use in higher education teaching and non-commercial academic research.
A commercialisation plan, developed by Nat Milton, won the UCL Entrepreneur's Challenge competition in 2003. This led to the formation of the original NeuroDelta Ltd company in collaboration with Insight Biotechnology Ltd, which raised DTI funding for a project to take forward potential Alzheimer's related therapeutic and diagnostic molecules. The project combined the use of in silico identification techniques with laboratory expertise in protein-protein interactions relevant to Alzheimer's disease. The antisense amyloid-ß peptides plus phosphorylated amyloid-ß compounds identified by Nat Milton were patented and taken to intention to grant in Europe at the end of the project in 2007.
The basis for application of research using in silico identification of protein-protein interactions for subsequent development as models for drug and diagnostic discovery underpins the activities of NeuroDelta Ltd. The in silico identification techniques also aided in the design of specific peptide aptamers that recognised the specific molecular targets being studied. The technologies developed by Nat Milton and NeuroDelta Ltd have been widely used in the discovery of novel peptides that have been developed as potential drugs. The kissorphin KiSS-1 metastasis suppressor protein derived peptides were identified as amyloid binding and the work covered in a UK patent for the use of kissorphin peptides in the treatment of Alzheimer's disease, Creutzfeldt Jakob disease and Diabetes Mellitus, that was granted to the University of Roehampton [GB2493313 Patent]. Compounds commercially developed from these techniques include the kissorphin peptides, which inhibit amyloid-ß, amylin and prion protein fragment induced neurotoxicity in vitro, plus the R9 peptide, which inhibits catalase interactions with amyloid-ß fibrils.
Neurodelta Ltd Contact Information:
Email: neurodelta.co.uk@gmail.com
NeuroDelta Ltd
Company number: 6222473
Registered in England & Wales
Current NeuroDelta Ltd Information
Original NeuroDelta Ltd Information